American Association for Cancer Research, Cancer Discovery, 8(13), p. 1762-1764, 2023
DOI: 10.1158/2159-8290.cd-23-0534
Full text: Unavailable
Summary:A disruptive clinical trial design allowed Drilon and colleagues to demonstrate proof of concept of the potential of PF-07284892 to overcome resistance mechanisms to targeted therapies in the clinic.See related article by Drilon et al., p. 1789 (7).